Get in touch with us!












      I accept conditions of use and privacy policy of this website.

    I want to receive updated information on the latest news.

    Get in touch with us!












        I accept conditions of use and privacy policy of this website.

      I want to receive updated information on the latest news.

      An Overview

      SODIUM-GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITOR

      Treatment of adults with insufficiently controlled type 2 diabetes mellitus to lower blood sugar levels, reduce the risk of stroke, heart attack or death and decrease the risk of end-stage kidney failure, worsening kidney function, need for hospitalization for heart failure and cardiovascular death.

      Description / Use

      Properties

      Advantages

      • Polymorphic Form I (EMA/374133/2013) confirmed.
      • Purity > 98%.
      • Two impurities identified.
      • Total impurities around 0.1%. Stable room temperature.

      Final Product Innovator Presentations

      • Monotherapy: Canagliflozin hemihydrate 100 mg; 300 mg.
      • Combined: Canagliflozin hemihydrate / Metformin hydrochloride 50 mg/850 mg; 50 mg/1.000 mg; 150 mg/850 mg; 150 mg/1.000 mg.

      Functional benefits

      • Can be applied in patients with cardiac and vascular disease and severe renal insufficiency.
      • Similar efficacy than other products of the same family.
      • Higher security due to less hypoglycemia risk than other products for same therapeutic line.

      * Items covered by valid patents are not offered or supplied for commercial use. Products under patent are available for R&D use only.

      Certifications

      Russian MOH
      Good Manufacturing Practice
      Good Manufacturing Practice
      Therapeutic Goods Administration - Australia
      National Sanitary Surveillance Agency Brazil
      U. S. FOOD AND DRUGS ADMINISTRATION
      Canada´s Food and Drugs Act and Regulations
      Ministry of Food and Drug Safety (MFDS) of Republic of Korea
      Federal Commission for the Protection against Sanitary Risk Mexico
      Pharmaceuticals and Medical Devices Agency - Japan
      General Directorate of Medicines, Supplies and Drugs - Peru
      European Directorate for the Quality of Medicines

      Our API

      Canagliflozin

      • Our API canagliflozin is manufactured in accordance with cGMP and stringent international quality standards.

      Canagliflozin

      • Our API canagliflozin is manufactured in accordance with cGMP and stringent international quality standards.

      Contact Us

      For more information
      about the products.